Cargando…

Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study

BACKGROUND: Preterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jie, Ren, Zhuxiao, Zhang, Chunyi, Rao, Yunbei, Zhong, Junjuan, Wang, Zhu, Liu, Zhipeng, Wei, Wei, Lu, Lijuang, Wen, Jiying, Liu, Guocheng, Liu, Kaiyan, Wang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114055/
https://www.ncbi.nlm.nih.gov/pubmed/30186329
http://dx.doi.org/10.1155/2018/5268057
_version_ 1783351125632614400
author Yang, Jie
Ren, Zhuxiao
Zhang, Chunyi
Rao, Yunbei
Zhong, Junjuan
Wang, Zhu
Liu, Zhipeng
Wei, Wei
Lu, Lijuang
Wen, Jiying
Liu, Guocheng
Liu, Kaiyan
Wang, Qi
author_facet Yang, Jie
Ren, Zhuxiao
Zhang, Chunyi
Rao, Yunbei
Zhong, Junjuan
Wang, Zhu
Liu, Zhipeng
Wei, Wei
Lu, Lijuang
Wen, Jiying
Liu, Guocheng
Liu, Kaiyan
Wang, Qi
author_sort Yang, Jie
collection PubMed
description BACKGROUND: Preterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and autogenic cord blood cells have been applied in the treatment of neonatal conditions such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD). OBJECTIVE: To assess the safety of autologous, volume- and red blood cell- (RBC-) reduced, noncryopreserved umbilical cord blood (UCB) cell infusion to preterm infants. METHOD: This study was a phase I, open-label, single-arm, single-center trial to evaluate the safety of autologous, volume- and RBC-reduced, noncryopreserved UCB cell (5 × 10(7)cells/kg) infusion for preterm infants <37 weeks gestational age. UCB cell characteristics, pre- and postinfusion vital signs, and laboratory investigations were recorded. Clinical data including mortality rates and preterm complications were recorded. RESULTS: After processing, (22.67 ± 4.05) ml UCB cells in volume, (2.67 ± 2.00) × 10(8) cells in number, with (22.67 ± 4.05) × 10(6) CD34+, (3.72 ± 3.25) × 10(5) colony forming cells (CFU-GM), and (99.7 ± 0.17%) vitality were infused to 15 preterm infants within 8 hours after birth. No adverse effects were noticed during treatment. All fifteen patients who received UCB infusion survived. The duration of hospitalization ranged from 4 to 65 (30 ± 23.6) days. Regarding preterm complications, no BPD, necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) was observed. There were 1/15 (7%) infant with intraventricular hemorrhage (IVH), 5/15 (33.3%) infants with ventilation-associated pneumonia, and 10/15 (66.67%) with anemia, respectively. CONCLUSIONS: Collection, preparation, and infusion of fresh autologous UCB cells to preterm infants is feasible and safe. Adequately powered randomized controlled studies are needed.
format Online
Article
Text
id pubmed-6114055
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61140552018-09-05 Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study Yang, Jie Ren, Zhuxiao Zhang, Chunyi Rao, Yunbei Zhong, Junjuan Wang, Zhu Liu, Zhipeng Wei, Wei Lu, Lijuang Wen, Jiying Liu, Guocheng Liu, Kaiyan Wang, Qi Stem Cells Int Research Article BACKGROUND: Preterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and autogenic cord blood cells have been applied in the treatment of neonatal conditions such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD). OBJECTIVE: To assess the safety of autologous, volume- and red blood cell- (RBC-) reduced, noncryopreserved umbilical cord blood (UCB) cell infusion to preterm infants. METHOD: This study was a phase I, open-label, single-arm, single-center trial to evaluate the safety of autologous, volume- and RBC-reduced, noncryopreserved UCB cell (5 × 10(7)cells/kg) infusion for preterm infants <37 weeks gestational age. UCB cell characteristics, pre- and postinfusion vital signs, and laboratory investigations were recorded. Clinical data including mortality rates and preterm complications were recorded. RESULTS: After processing, (22.67 ± 4.05) ml UCB cells in volume, (2.67 ± 2.00) × 10(8) cells in number, with (22.67 ± 4.05) × 10(6) CD34+, (3.72 ± 3.25) × 10(5) colony forming cells (CFU-GM), and (99.7 ± 0.17%) vitality were infused to 15 preterm infants within 8 hours after birth. No adverse effects were noticed during treatment. All fifteen patients who received UCB infusion survived. The duration of hospitalization ranged from 4 to 65 (30 ± 23.6) days. Regarding preterm complications, no BPD, necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) was observed. There were 1/15 (7%) infant with intraventricular hemorrhage (IVH), 5/15 (33.3%) infants with ventilation-associated pneumonia, and 10/15 (66.67%) with anemia, respectively. CONCLUSIONS: Collection, preparation, and infusion of fresh autologous UCB cells to preterm infants is feasible and safe. Adequately powered randomized controlled studies are needed. Hindawi 2018-08-15 /pmc/articles/PMC6114055/ /pubmed/30186329 http://dx.doi.org/10.1155/2018/5268057 Text en Copyright © 2018 Jie Yang et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yang, Jie
Ren, Zhuxiao
Zhang, Chunyi
Rao, Yunbei
Zhong, Junjuan
Wang, Zhu
Liu, Zhipeng
Wei, Wei
Lu, Lijuang
Wen, Jiying
Liu, Guocheng
Liu, Kaiyan
Wang, Qi
Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
title Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
title_full Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
title_fullStr Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
title_full_unstemmed Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
title_short Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
title_sort safety of autologous cord blood cells for preterms: a descriptive study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114055/
https://www.ncbi.nlm.nih.gov/pubmed/30186329
http://dx.doi.org/10.1155/2018/5268057
work_keys_str_mv AT yangjie safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT renzhuxiao safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT zhangchunyi safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT raoyunbei safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT zhongjunjuan safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT wangzhu safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT liuzhipeng safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT weiwei safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT lulijuang safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT wenjiying safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT liuguocheng safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT liukaiyan safetyofautologouscordbloodcellsforpretermsadescriptivestudy
AT wangqi safetyofautologouscordbloodcellsforpretermsadescriptivestudy